A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
Latest Information Update: 05 Nov 2024
Price :
$35 *
At a glance
- Drugs Islatravir/Lenacapavir (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms ISLEND-2
- Sponsors Gilead Sciences
- 01 Nov 2024 Status changed from not yet recruiting to recruiting.
- 11 Oct 2024 New trial record